Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Latent Tuberculosis in Type 2 Diabetes

    NCT06874725 · start 2018-04-18

    Registered record
    Registry ID
    NCT06874725
    Conditions
    Latent Tuberculosis Infection
    Interventions
    Rifapentine and Isoniazid for 3 months; Isoniazid (INH) daily for 9 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2018-04-18
    Completion
    2025-04-18
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection
    InterventionRifapentine and Isoniazid for 3 months; Isoniazid (INH) daily for 9 months
    PhasePhase 4
    Registry statusActive not recruiting

  • Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

    NCT03478033 · start 2018-04-15

    Registered record
    Registry ID
    NCT03478033
    Conditions
    Tuberculosis, Pulmonary; AIDS
    Interventions
    Rifampicin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-04-15
    Completion
    2020-12-31
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; AIDS
    InterventionRifampicin; Rifabutin
    PhaseNot applicable
    Registry statusUnknown

  • Pretomanid in Adults With Hepatic Impairment

    NCT02422524 · start 2018-03-29

    Registered record
    Registry ID
    NCT02422524
    Conditions
    Tuberculosis
    Interventions
    PA-824
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-03-29
    Completion
    2023-11-17
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPA-824
    PhasePhase 1
    Registry statusTerminated

  • Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

    NCT03474198 · start 2018-03-21

    Registered record
    Registry ID
    NCT03474198
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Linezolid; Clofazimine; Rifapentine; Levofloxacin; Bedaquiline; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-03-21
    Completion
    2022-01-20
    Enrolment
    675

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampicin; Isoniazid; Pyrazinamide; Ethambutol +6 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

    NCT03086486 · start 2017-11-21

    Registered record
    Registry ID
    NCT03086486
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pre-XDR-TB; XDR-TB
    Interventions
    Pretomanid; Linezolid; Bedaquiline; Placebo Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-21
    Completion
    2022-02-08
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +3 more
    InterventionPretomanid; Linezolid; Bedaquiline; Placebo Linezolid
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

    NCT05896930 · start 2017-11-09

    Registered record
    Registry ID
    NCT05896930
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Meropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV; Amoxicillin/CA twice daily; Rifampicin 35 mg/kg; Meropenem 6g IV over 60 minutes; Rifafour e-275; Meropenem 4g IV; Amoxicillin/CA once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-09
    Completion
    2021-01-04
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionMeropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV +6 more
    PhasePhase 2
    Registry statusCompleted

  • Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

    NCT03174184 · start 2017-08-23

    Registered record
    Registry ID
    NCT03174184
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD; Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet; Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-23
    Completion
    2022-05-13
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD +2 more
    PhasePhase 2
    Registry statusCompleted

  • Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

    NCT03089983 · start 2017-08-21

    Registered record
    Registry ID
    NCT03089983
    Conditions
    Opioid Dependence; Addiction; HIV/AIDS; Tuberculosis; Hepatitis
    Interventions
    Isoniazid; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-08-21
    Completion
    2024-04-04
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence; Addiction; HIV/AIDS; Tuberculosis +1 more
    InterventionIsoniazid; Rifapentine
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin

    NCT02975570 · start 2017-08

    Registered record
    Registry ID
    NCT02975570
    Conditions
    Tuberculosis Multi Drug Resistant Active
    Interventions
    Delamanid; Linezolid; Levofloxacin; Pyrazinamide; WHO MDR-TB regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2017-08
    Completion
    2022-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Multi Drug Resistant Active
    InterventionDelamanid; Linezolid; Levofloxacin; Pyrazinamide +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • The Impact of Pharmacists' Interventions on the Quality of Life of HIV-TB Co-infection Outpatients in Indonesia

    NCT04325438 · start 2017-04-01

    Registered record
    Registry ID
    NCT04325438
    Conditions
    Pharmaceutical Care; HIV/AIDS; Tuberculosis
    Interventions
    Pharmaceutical Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2019-03-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmaceutical Care; HIV/AIDS; Tuberculosis
    InterventionPharmaceutical Care
    PhaseNot applicable
    Registry statusCompleted

  • Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

    NCT02651259 · start 2017-03-13

    Registered record
    Registry ID
    NCT02651259
    Conditions
    Tuberculosis
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2019-04-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Intravenous Treatment of Tuberculosis

    NCT04150367 · start 2017-03-03

    Registered record
    Registry ID
    NCT04150367
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Ethambutol; Rifampicin; Isoniazid; Ethambutol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-03-03
    Completion
    2018-07-14
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Ethambutol; Rifampicin +2 more
    PhaseNot recorded
    Registry statusTerminated

  • PK/PD of Ertapenem In Patients With TB

    NCT01730664 · start 2017-01-26

    Registered record
    Registry ID
    NCT01730664
    Conditions
    PK of Ertapenem in TB Patients
    Interventions
    ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01-26
    Completion
    2017-07-13
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPK of Ertapenem in TB Patients
    Interventionertapenem
    PhasePhase 2
    Registry statusCompleted

  • Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

    NCT02589782 · start 2017-01

    Registered record
    Registry ID
    NCT02589782
    Conditions
    Tuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-01
    Completion
    2022-08-05
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted